Active substance
Trifluridine
- SFDA 2
- US FDA 3
- US price lines 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TFT THILO 1% EYE DROPS | 1 % | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 29.50 | Generic · Prescription | DR. THILO LABORATORIES | Withdrawn by MAH · Not Marketed |
| VIROMIDIN EYE DROPS 1% | 1 % | Eye drops · Ocular use | 1 Dropper Container | SAR 22.95 | NCE · Prescription | ALCON CUSI | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VIROPTIC | 1% | solution/drops · ophthalmic | MONARCH PHARMS | Prescription | 10 Apr 1980 |
| TRIFLURIDINE | 1% | solution/drops · ophthalmic | SANDOZ | Prescription | 6 Oct 1995 |
| TRIFLURIDINE | 1% | solution/drops · ophthalmic | HIKMA PHARMS | Discontinued | 28 Jul 2017 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TRIFLURIDINE 1% EYE DROPS | $23.02208 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 2 Aug 2023 LONSURF — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Trifluridine
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.